Announced Tue, 30 Sept · 17:32 IST

Outcome of 38th Annual General Meeting in compliance with Regulation 30 of SEBI (LODR) Regulation 2015

Board & Shareholder Meetings View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Fredun Pharmaceuticals held its 38th AGM on 30th September 2025 via video conferencing, starting at 9:00 AM and concluding at 9:25 AM. The meeting was chaired by Dr. Daulat Nariman Medhora, while Managing Director & CFO Fredun Medhora presented the performance highlights of FY 2024-25. Eight resolutions were put to vote, including adoption of FY25 audited financials, declaration of a 7% dividend on equity shares, re-appointment of Mr. Fredun Medhora as Managing Director (retiring by rotation), and ratification of the Cost Auditor's remuneration for FY26. Two Special Resolutions covered approval for related party transactions and the appointment of two new Non-Executive Independent Directors, Mr. Anshu Agarwal and Ms. Sonal Dharmin Desai. Ms. Kala Agarwal was appointed as Secretarial Auditor for five years. Voting results from remote e-voting and AGM e-voting are pending and will be submitted within two working days.

Likely market impact

The 7% dividend declaration is a positive signal for shareholders seeking income. New independent director appointments and RPT approval are routine governance items, while voting outcomes are still awaited and could drive short-term sentiment once announced.